FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.

Autor: Agrawal S; United States Food and Drug Administration, Silver Spring, MD, United States., Lee C; United States Food and Drug Administration, Silver Spring, Maryland, United States., Pierce WF; Food and Drug Administration, Silver Spring, Maryland, United States., Everhart E; United States Food and Drug Administration, Silver Spring, MD, United States., King-Ducre A; Food and Drug Administration, Silver Spring, Maryland, United States., Royce M; United States Food and Drug Administration, Silver Spring, Maryland, United States., Osgood CL; United States Food and Drug Administration, Silver Spring, MD, United States., Amiri-Kordestani L; Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, United States., Chiu HJ; Food and Drug Administration, Silver Spring, Maryland, United States., Ricks TK; United States Food and Drug Administration, Silver Spring, MD, United States., Pan L; United States Food and Drug Administration, Silver Spring, Maryland, United States., Fourie Zirkelbach J; United States Food and Drug Administration, Silver Spring, Maryland, United States., Charlab R; United States Food and Drug Administration, Silver Spring, MD, United States., Pacanowski M; United States Food and Drug Administration, Silver Spring, MD, United States., Kim T; United States Food and Drug Administration, Silver Spring, MD, United States., Pazdur R; United States Food and Drug Administration, Silver Spring, MD, United States., Kluetz PG; Food and Drug Administration, Silver Spring, MD, United States., Gao JJ; United States Food and Drug Administration, Silver Spring, MD, United States.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 08. Date of Electronic Publication: 2024 Oct 08.